Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. Lam TC, Tsang KC, Choi HC, Lee VH, et al. Lung Cancer 2021;159:18-26.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lam TC, Tsang KC, Choi HC, Lee VH, et al. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. Lung Cancer 2021;159:18-26.
PMID: 34303276